Impaired LAIR-1-mediated immune control due to collagen degradation in fibrosis
- PMID: 38696927
- DOI: 10.1016/j.jaut.2024.103219
Impaired LAIR-1-mediated immune control due to collagen degradation in fibrosis
Abstract
Tissue repair is disturbed in fibrotic diseases like systemic sclerosis (SSc), where the deposition of large amounts of extracellular matrix components such as collagen interferes with organ function. LAIR-1 is an inhibitory collagen receptor highly expressed on tissue immune cells. We questioned whether in SSc, impaired LAIR-1-collagen interaction is contributing to the ongoing inflammation and fibrosis. We found that SSc patients do not have an intrinsic defect in LAIR-1 expression or function. Instead, fibroblasts from healthy controls and SSc patients stimulated by soluble factors that drive inflammation and fibrosis in SSc deposit disorganized collagen products in vitro, which are dysfunctional LAIR-1 ligands. This is dependent of matrix metalloproteinases and platelet-derived growth factor receptor signaling. In support of a non-redundant role of LAIR-1 in the control of fibrosis, we found that LAIR-1-deficient mice have increased skin fibrosis in response to repeated injury and in the bleomycin mouse model for SSc. Thus, LAIR-1 represents an essential control mechanism for tissue repair. In fibrotic disease, excessive collagen degradation may lead to a disturbed feedback loop. The presence of functional LAIR-1 in patients provides a therapeutic opportunity to reactivate this intrinsic negative feedback mechanism in fibrotic diseases.
Keywords: CD305; Collagen; Fibrosis; LAIR-1; Systemic sclerosis; Tissue repair.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest DF, MR and MEMG were full time employees of Boehringer Ingelheim. TRDJR was a principal investigator in the immune catalyst program of GlaxoSmith-Kline, which was an independent research program. He did not receive any financial support. Currently, TRDJR is an employee of Abbvie where he holds stock. TRDJR had no part in the design and interpretation of the study results after he started at Abbvie. LM's research lab has received financial support for investigator-initiated studies from Boehringer Ingelheim, NextCure and NGM biopharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases